Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Goodwill & Intangibles (2016 - 2025)

RedHill Biopharma has reported Goodwill & Intangibles over the past 15 years, most recently at $5.3 million for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 4.62% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, down 4.62% year-over-year, with the annual reading at $5.3 million for FY2025, 4.62% down from the prior year.
  • Goodwill & Intangibles was $5.3 million for Q4 2025 at RedHill Biopharma, down from $5.5 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $89.4 million in Q4 2021 and troughed at $5.3 million in Q4 2025.
  • The 5-year median for Goodwill & Intangibles is $11.8 million (2023), against an average of $39.9 million.
  • Year-over-year, Goodwill & Intangibles soared 442.88% in 2021 and then plummeted 93.56% in 2022.
  • A 5-year view of Goodwill & Intangibles shows it stood at $89.4 million in 2021, then plummeted by 93.56% to $5.8 million in 2022, then skyrocketed by 104.76% to $11.8 million in 2023, then plummeted by 52.94% to $5.5 million in 2024, then decreased by 4.62% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Goodwill & Intangibles are $5.3 million (Q4 2025), $5.5 million (Q2 2025), and $5.5 million (Q4 2024).